CASE Direct #3: Destiny-Breast 09 Case Study
Agenda 9:00-9:20 Keynote speech - Destiny-Breast 09 Phase III clinical research and progress Dr. Sara M Tolaney, Dana Farber Cancer Center, Harvard Medical School 9:20-9:50 Expert commentary -To elaborate on the past and present of the DESTINY-Breast series of studies, predict the results of DB09 from DB03, who will be the overlord of advanced breast cancer research? From clinical data perspective: Dr. Sheng Luo, Duke University From clinical mechanism perspective: Dr. Youwen